Reduction of cardiovascular structural changes by Nifedipine GITS in essential hypertensive patients

Blood Pressure

Volumn 7, Issue 3, 1998, Pages 160-169

  Agabiti Rosei, Enrico ^a   Zulli, Roberto ^a   Muiesan, Maria Lorenza ^a   Salvetti, Massimo ^a   Rizzoni, Damiano ^a   Corbellini, Claudia ^a   Monteduro, Cristina ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Calcium antagonist; Hydrochlorothiazide; LVH regression; Minimal vascular resistance

Indexed keywords

HYDROCHLOROTHIAZIDE; NIFEDIPINE;

ADULT; AGED; ANKLE EDEMA; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; GINGIVA HYPERTROPHY; HEADACHE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART RATE; HUMAN; M MODE ECHOCARDIOGRAPHY; MALE; PLETHYSMOGRAPHY; PRIORITY JOURNAL; SYSTEMIC VASCULAR RESISTANCE; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DELAYED-ACTION PREPARATIONS; DIURETICS; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HEART VENTRICLES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; MYOCARDIUM; NIFEDIPINE; ORGAN SIZE; SODIUM CHLORIDE SYMPORTER INHIBITORS; VASCULAR RESISTANCE; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 0031661085     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370598437376     Document Type: Article

References (44)

1. Kannel WB, Gordon T, Offut T. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence and mortality in the Framingham study. Ann Intern Med 1969; 71: 89-95.
2. Levy D. Left ventricular hypertrophy. Epidemiological insights from the Framingham Heart Study. Drugs 1988; (Suppl 5): 1-5.
3. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-6.
4. Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105: 173-8.
5. Zanchetti A. Goals of antihypertensive treatment: prevention of cardiovascular events and prevention of organ damage. Blood Pressure 1992; 1: 201-11.
6. Frohlich ED, Tarazi RC. Is arterial pressure the sole factor responsible for hypertensive cardiac hypertrophy? Am J Cardiol 1979; 44: 459-63.
7. Agabiti-Rosei E, Muiesan ML. Reversal of cardiovascular structural changes during long-term antihypertensive therapy. J Hum Hypertens 1991; 5(Suppl 1): 41-7.
8. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
9. Cruickshank JM, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992; 6: 85-90.
10. Schmieder R, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A metaanalysis of randomized double-blind studies. JAMA 1996; 275: 1507-13.
11. Neaton JD, Grimm RH, Prineas RJ, Stamler J, Grandits GA, Emler P, et al on behalf of the Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study. Final results. JAMA 1993; 270: 713-24.
12. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ for the VA Cooperative Study Group on Antihypertensive Agents. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Comparison of six antihypertensive agents. The Department of Veterans' Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 1997; 95: 2007-14.
13. Phillips RA, Ardeljan M, Shimabukuro S, et al. Normalization of left ventricular mass and associated changes in neurohormones and atrial natriuretic peptide after 1 year of sustained Nifedipine therapy for severe hypertension. J Am Coll Cardiol 1991; 17: 1595-1602.
14. Sahn DJ, DeMaria A, Kisslo J, Weyman A. The Committee on M-mode standardization of the American Society of Echocardiography: recommendations regarding quanticization in M-mode echocardiography. Results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-83.
15. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment on left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-8.
16. Devereux RB, Lutas EM, Casale PN, et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984; 4: 1222-30.
17. Reicheck N, Devereux RB. Reliable estimation of peak left ventricular systolic pressure by M-mode echographic-determined end-diastolic relative wall thickness: identification of severe valvular aortic stenosis in adult patients. Am Heart J 1982; 103: 202-3.
18. Pedrinelli R, Taddei S, Spessot M, Salvetti A. Maximal postischemic forearm vasodilatation. A reassessment of the method. J Hypertens 1987; 5(Suppl 5): S431-S433.
19. Agabiti-Rosei E, Rizzoni D, Castellano M, et al. Media:lumen ratio in human small resistance arteries is related to forearm minimal vascular resistance. J Hypertens 1995; 13: 341-447.
20. de Simone G, Daniels SR, Devereux RB, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and of the impact of overweight. J Am Coll Cardiol 1992; 20: 1251-60.
21. Koren MJ, Ulin RJ, Laragh JH, Devereux RB. Reduction of left ventricular mass during treatment of essential hypertension is associated with improved prognosis. Am J Hypertens 1991; 4: 1A.
22. Yurenev AP, Dyakonova HG, Novikov ID, Vitolo A, Pahl L, Haynemann G, et al. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy. Am J Hypertens 1992; 5(Suppl): S182-S189.
23. Levy D, Salomon M, D'Agostino RB, Bolanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 80: 1786-93.
24. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995; 13: 1091-5.
25. Alderman MH, Cohen H, Roque R, Madhavan S. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 1997; 349: 594-8.
26. Chung M, Reitberg DP, Gaffney M, Singleton W. Clinical pharmacokinetics of Nifedipine gastrointestinal therapeutic system. Am J Med 1987; 83(Suppl 6B): 10-4.
27. Krakoff LR, Bravo EL, Tuck ML, Friedman CP the MATH Study Group. Nifedipine gastrointestinal therapeutic system in the treatment of hypertension. Am J Hypertens 1990; 3: S318-S325.
28. Tuck ML, Bravo EL, Krakoff LR, Friedman CP the Modern Approach to the Treatment of Hypertension Study Group. Endocrine and renal effects of Nifedipine gastrointestinal therapeutic system in patients with essential hypertension. Am J Hypertens 1990; 3: S333-S341.
29. Dey HM, Soufer R, Hoffer P, Wackers FJT, Black HR. Comparison of Nifedipine GITS and hydrochlorothiazide in the management of elderly patients with stage I-III diastolic hypertension. Am J Hypertens 1996; 9: 589-606.
30. Agabiti-Rosei E, Ambrosioni E, dal Palu' C, Muiesan ML, Zanchetti A on behalf of the RACE Study Group. ACE-inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (Ramipril Cardioprotective Evaluation) study. J Hypertens 1995; 13: 1325-35.
31. Muiesan ML, Agabiti-Rosei E, Romanelli G, Alari G, Barbier P, Fiorentini C. Left ventricular systolic function in relation to withdrawal of different treatments in hypertensives with left ventricular hypertrophy. J Hypertens 1988; 6(Suppl 4): S97-S100.
32. Trimarco B, De Luca N, Ricciardelli B, et al. Cardiac function in systemic hypertension before and after reversal of left ventricular hypertrophy. Am J Cardiol 1988; 62: 745-50.
33. Schmieder RE, Messerli FH, Sturgill D, Garavaglia GE, Nunez BD. Cardiac performance after reduction of myocardial hypertrophy. Am J Med 1989; 87: 22-7.
34. Muiesan ML, Agabiti-Rosei E, Romanelli G, et al. Improved left ventricular systolic and diastolic function after regression of cardiac hypertrophy, treatment withdrawal and redevelopment of hypertension. J Cardiovasc Pharmacol 1991; 17: S179-S81.
35. Inouye IK, Massie BM, Loge D, Simpson P, Tabau JF. Failure of antihypertensive therapy with diuretic, beta-blocking and calcium channel blocking drugs to consistently reverse left ventricular diastolic filling abnormalities. Am J Cardiol 1984; 53: 1583-7.
36. Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1982; 63: 347-504.
37. Sivertsson R. The hemodynamic importance of structural vascular changes in essential hypertension. Acta Physiol Scand 1970; 343: 14-9.
38. Folkow B. The Fourth Volhard Lecture. Cardiovascular structural adaptation: its role in the initiation and maintenance of primary hypertension. Clin Sci Mol Med (Suppl) 1978; 4: S3-S22.
39. Virdis A, Ghiadoni S, Lucarini A, Di Legge V, Taddei S, Salvetti A. Presence of cardiovascular structural changes in essential hypertensive patients with coronary microvascular disease and effects of long-term treatment. Am J Hypertens 1996; 9: 361-9.
40. Agabiti-Rosei E, Muiesan ML, Muiesan G. Regression of structural alterations in hypertension. Am J Hypertens 1989; 2: S70-S75.
41. Agabiti-Rosei E, Muiesan ML, Geri A, Romanelli G, Montani G, Muiesan G. Relation between cardiac hypertrophy and forearm vascular structural changes before and during long-term antihypertensive treatment. Am J Med 1988; 84(Suppl 3A): 125-8.
42. Schiffrin EL, Deng LY. Structure and function of resistance arteries of hypertensive patients treated with a beta-blocker or a calcium channel antagonist. J Hypertens 1996; 14: 1247-57.
43. Agabiti-Rosei E, Muiesan ML, Rizzoni D, et al. Cardiovascular structural changes and calcium antagonist therapy in patients with hypertension. J Cardiovasc Pharmacol 1994: 24(Suppl A): S37-S43.
44. Brown MJ, Castaighe A, Ruilope LM, Mancia G, Rosenthal T, de Leew PW, et al. INSIGHT: International Nifedipine GITS Study intervention as a goal in hypertension treatment. J Human Hypertens 1996; 10(Suppl 3): S157-S160.